OliX Pharmaceuticals adds New Zealand MedSafe to OLX72021 hair-loss trial approvals in corrected filing

Bitget2026/10/08 08:24

OliX Pharmaceuticals issued a correction to its disclosure on OLX72021’s Phase 1b/2a trial plan for androgenetic alopecia. The update adds New Zealand MedSafe as an approving authority, alongside Australia’s Bellberry HREC. Trial footprint expands to Australia and New Zealand, with about 10 sites in Australia and about four in New Zealand. Target enrollment was raised to 158 participants from 120. OliX received CRO notice of MedSafe’s approval on Oct. 8, 2026, following a Sept. 8, 2026 application. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OliX Pharmaceuticals Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261008900549), on October 08, 2026, and is solely responsible for the information contained therein.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

OliX Pharmaceuticals issued a correction to its disclosure on OLX72021’s Phase 1b/2a trial plan for androgenetic alopecia.
The update adds New Zealand MedSafe as an approving authority, alongside Australia’s Bellberry HREC.
Trial footprint expands to Australia and New Zealand, with about 10 sites in Australia and about four in New Zealand.
Target enrollment was raised to 158 participants from 120.
OliX received CRO notice of MedSafe’s approval on Oct. 8, 2026, following a Sept. 8, 2026 application.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OliX Pharmaceuticals Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261008900549), on October 08, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

OliX Pharmaceuticals adds New Zealand MedSafe to OLX72021 hair-loss trial approvals in corrected filing

You may also like

Crypto prices